You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZaleplon
Accession NumberDB00962  (APRD00411)
TypeSmall Molecule
GroupsApproved, Illicit, Investigational
DescriptionZaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Structure
Thumb
Synonyms
3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide
External Identifiers
  • DEA No. 2781
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sonatacapsule5 mg/1oralPhysicians Total Care, Inc.2007-09-05Not applicableUs
Sonatacapsule5 mg/1oralPfizer Laboratories Div Pfizer Inc1999-08-13Not applicableUs
Sonatacapsule10 mg/1oralPfizer Laboratories Div Pfizer Inc1999-08-13Not applicableUs
Sonatacapsule10 mg/1oralPhysicians Total Care, Inc.2004-04-01Not applicableUs
Starnoccapsule10 mgoralPfizer Canada IncNot applicableNot applicableCanada
Starnoccapsule5 mgoralServier Canada Inc2000-06-272007-09-27Canada
Starnoccapsule10 mgoralServier Canada Inc2000-06-272007-09-27Canada
Starnoccapsule5 mgoralPfizer Canada IncNot applicableNot applicableCanada
Zaleploncapsule5 mg/1oralbryant ranch prepack2008-05-01Not applicableUs
Zaleploncapsule10 mg/1oralRebel Distributors Corp.2008-05-01Not applicableUs
Zaleploncapsule5 mg/1oralRebel Distributors Corp.2008-05-01Not applicableUs
Zaleploncapsule10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-05Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Zaleploncapsule, gelatin coated10 mg/1oralUpsher Smith Laboratories, Inc.2008-06-06Not applicableUs
Zaleploncapsule10 mg/1oralH.J. Harkins Company, Inc.2010-12-15Not applicableUs
Zaleploncapsule5 mg/1oralRoxane Laboratories, Inc2008-06-06Not applicableUs
Zaleploncapsule5 mg/1oralRebel Distributors Corp2009-05-05Not applicableUs
Zaleploncapsule10 mg/1oralAurobindo Pharma Limited2008-06-06Not applicableUs
Zaleploncapsule10 mg/1oralSt Marys Medical Park Pharmacy2010-12-15Not applicableUs
Zaleploncapsule10 mg/1oralUnichem Pharmaceuticals (USA), Inc.2009-05-05Not applicableUs
Zaleploncapsule5 mg/1oralMylan Pharmaceuticals Inc.2008-06-06Not applicableUs
Zaleploncapsule5 mg/1oralPd Rx Pharmaceuticals, Inc.2008-06-06Not applicableUs
Zaleploncapsule5 mg/1oralNorthstar Rx LLC2010-06-23Not applicableUs
Zaleploncapsule10 mg/1oralA S Medication Solutions Llc2008-06-06Not applicableUs
Zaleploncapsule10 mg/1oralRoxane Laboratories, Inc2008-06-06Not applicableUs
Zaleploncapsule10 mg/1oralRebel Distributors Corp2009-05-05Not applicableUs
Zaleploncapsule5 mg/1oralDispensing Solutions, Inc.2008-06-06Not applicableUs
Zaleploncapsule10 mg/1oralAidarex Pharmaceuticals LLC2009-05-05Not applicableUs
Zaleploncapsule10 mg/1oralDIRECT RX2015-01-01Not applicableUs
Zaleploncapsule10 mg/1oralMylan Pharmaceuticals Inc.2008-06-06Not applicableUs
Zaleploncapsule10 mg/1oralA S Medication Solutions Llc2008-06-06Not applicableUs
Zaleploncapsule10 mg/1oralNorthstar Rx LLC2010-06-23Not applicableUs
Zaleploncapsule10 mg/1oralPhysicians Total Care, Inc.2008-06-19Not applicableUs
Zaleploncapsule5 mg/1oralTeva Pharmaceuticals USA Inc2008-06-06Not applicableUs
Zaleploncapsule5 mg/1oralRebel Distributors Corp2009-05-05Not applicableUs
Zaleploncapsule5 mg/1oralAscend Laboratories, LLC2010-12-15Not applicableUs
Zaleploncapsule5 mg/1oralAidarex Pharmaceuticals LLC2009-05-05Not applicableUs
Zaleploncapsule10 mg/1oralbryant ranch prepack2009-05-05Not applicableUs
Zaleploncapsule, gelatin coated5 mg/1oralUpsher Smith Laboratories, Inc.2008-06-06Not applicableUs
Zaleploncapsule10 mg/1oralUnit Dose Services2008-06-06Not applicableUs
Zaleploncapsule5 mg/1oralUnichem Pharmaceuticals (USA), Inc.2009-05-05Not applicableUs
Zaleploncapsule5 mg/1oralPhysicians Total Care, Inc.2008-06-19Not applicableUs
Zaleploncapsule10 mg/1oralAscend Laboratories, LLC2010-12-15Not applicableUs
Zaleploncapsule10 mg/1oralTeva Pharmaceuticals USA Inc2008-06-06Not applicableUs
Zaleploncapsule5 mg/1oralPd Rx Pharmaceuticals, Inc.2011-12-02Not applicableUs
Zaleploncapsule10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2009-05-05Not applicableUs
Zaleploncapsule5 mg/1oralAurobindo Pharma Limited2008-06-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SonataCapsule, hard5 mgOral useMeda Ab1999-03-12Not applicableEu
SonataCapsule, hard10 mgOral useMeda Ab1999-03-12Not applicableEu
SonataCapsule, hard5 mgOral useMeda Ab1999-03-12Not applicableEu
SonataCapsule, hard 110 mgOral useMeda Ab1999-03-12Not applicableEu
SonataCapsule, hard5 mgOral useMeda Ab1999-03-12Not applicableEu
SonataCapsule, hard10 mgOral useMeda Ab1999-03-12Not applicableEu
International Brands
NameCompany
ZalaplonNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIS62U433RMH
CAS number151319-34-5
WeightAverage: 305.3339
Monoisotopic: 305.127660127
Chemical FormulaC17H15N5O
InChI KeyInChIKey=HUNXMJYCHXQEGX-UHFFFAOYSA-N
InChI
InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
IUPAC Name
N-(3-{3-cyanopyrazolo[1,5-a]pyrimidin-7-yl}phenyl)-N-ethylacetamide
SMILES
CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentPhenylpyrimidines
Alternative Parents
Substituents
  • 4-phenylpyrimidine
  • Acetanilide
  • Pyrazolopyrimidine
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Acetamide
  • Tertiary carboxylic acid amide
  • Pyrazole
  • Azole
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Nitrile
  • Carbonitrile
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of short-term treatment of insomnia in adults.
PharmacodynamicsZaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABAA-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, ο1) receptors.
Mechanism of actionZaleplon exerts its action through subunit modulation of the GABABZ receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.
Related Articles
AbsorptionAbsorption Zaleplon is rapidly and almost completely absorbed following oral administration.
Volume of distribution
  • 1.4 L/kg
Protein bindingApproximately 60% (in vitro plasma protein binding).
Metabolism

Zaleplon is primarily metabolized by aldehyde oxidase.

SubstrateEnzymesProduct
Zaleplon
desethylzaleplonDetails
Route of eliminationZaleplon is metabolized primarily by the liver and undergoes significant presystemic metabolism. After oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.
Half lifeApproximately 1 hour
Clearance
  • 1 L/h/kg
ToxicitySide effects include abdominal pain, amnesia, dizziness, drowsiness, eye pain, headache, memory loss, menstrual pain, nausea, sleepiness, tingling, weakness
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9751
Caco-2 permeable+0.5973
P-glycoprotein substrateNon-substrate0.6094
P-glycoprotein inhibitor INon-inhibitor0.5232
P-glycoprotein inhibitor IIInhibitor0.8239
Renal organic cation transporterNon-inhibitor0.745
CYP450 2C9 substrateNon-substrate0.8607
CYP450 2D6 substrateNon-substrate0.8551
CYP450 3A4 substrateSubstrate0.6341
CYP450 1A2 substrateNon-inhibitor0.5
CYP450 2C9 inhibitorInhibitor0.5986
CYP450 2D6 inhibitorNon-inhibitor0.9507
CYP450 2C19 inhibitorNon-inhibitor0.5238
CYP450 3A4 inhibitorNon-inhibitor0.8396
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7673
Ames testNon AMES toxic0.5372
CarcinogenicityNon-carcinogens0.6481
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6277 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9806
hERG inhibition (predictor II)Non-inhibitor0.8931
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals research and development inc sub king pharmaceuticals inc
  • Aurobindo pharma ltd
  • Cipla ltd
  • Mylan pharmaceuticals inc
  • Orchid healthcare div orchid chemicals and pharmaceuticals ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Unichem laboratories ltd
  • Upsher smith laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Capsule, hardOral use10 mg
Capsule, hardOral use5 mg
Capsule, hard 1Oral use10 mg
Capsuleoral10 mg
Capsuleoral5 mg
Capsuleoral10 mg/1
Capsuleoral5 mg/1
Capsule, gelatin coatedoral10 mg/1
Capsule, gelatin coatedoral5 mg/1
Prices
Unit descriptionCostUnit
Sonata 10 mg capsule6.83USD capsule
Sonata 5 mg capsule5.26USD capsule
Zaleplon 5 mg capsule2.13USD capsule
Zaleplon 10 mg capsule2.09USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point157-159 °CNot Available
logP0.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0403 mg/mLALOGPS
logP2ALOGPS
logP1.53ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)0.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area74.29 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity97.24 m3·mol-1ChemAxon
Polarizability32.09 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-01ot-3391000000-78a75199aa0ab8c426beView in MoNA
References
Synthesis Reference

Farhan Aslam, “Polymorphs of zaleplon and methods for the preparation thereof.” U.S. Patent US20020072527, issued June 13, 2002.

US20020072527
General References
  1. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T: Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004 Jul;19(5):305-22. [PubMed:15252823 ]
  2. Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. [PubMed:15037809 ]
  3. Ramakrishnan K, Scheid DC: Treatment options for insomnia. Am Fam Physician. 2007 Aug 15;76(4):517-26. [PubMed:17853625 ]
  4. Barbera J, Shapiro C: Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf. 2005;28(4):301-18. [PubMed:15783240 ]
  5. Dooley M, Plosker GL: Zaleplon: a review of its use in the treatment of insomnia. Drugs. 2000 Aug;60(2):413-45. [PubMed:10983740 ]
  6. Holm KJ, Goa KL: Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89. [PubMed:10804040 ]
  7. Patat A, Paty I, Hindmarch I: Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol. 2001 Jul;16(5):369-392. [PubMed:12404558 ]
External Links
ATC CodesN05CF03
AHFS Codes
  • 28:24.92
PDB EntriesNot Available
FDA labelDownload (66.1 KB)
MSDSDownload (57.6 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Zaleplon.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zaleplon.
AmiodaroneThe metabolism of Zaleplon can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amperozide.
AprepitantThe serum concentration of Zaleplon can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Asenapine.
AtazanavirThe metabolism of Zaleplon can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Zaleplon can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Azaperone.
AzelastineZaleplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zaleplon.
BaclofenThe risk or severity of adverse effects can be increased when Zaleplon is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Zaleplon is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Zaleplon can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Zaleplon can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Zaleplon can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Zaleplon can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
BrimonidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zaleplon.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Zaleplon.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Zaleplon.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zaleplon.
ButacaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zaleplon.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zaleplon.
CarbinoxamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carisoprodol.
CeritinibThe serum concentration of Zaleplon can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zaleplon.
ChlormezanoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zaleplon.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorzoxazone.
CimetidineThe metabolism of Zaleplon can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zaleplon.
CitalopramThe risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram.
ClarithromycinThe metabolism of Zaleplon can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Zaleplon can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zaleplon.
ClotrimazoleThe metabolism of Zaleplon can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Zaleplon.
CobicistatThe metabolism of Zaleplon can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Zaleplon.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Zaleplon.
ConivaptanThe serum concentration of Zaleplon can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Zaleplon can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zaleplon.
CyclosporineThe metabolism of Zaleplon can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cyproheptadine.
DabrafenibThe serum concentration of Zaleplon can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zaleplon.
DapoxetineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dapoxetine.
DarunavirThe metabolism of Zaleplon can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Zaleplon can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Zaleplon can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Zaleplon can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Zaleplon is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Detomidine.
DexamethasoneThe serum concentration of Zaleplon can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zaleplon.
DextromoramideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zaleplon.
DezocineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Zaleplon.
DifenoxinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Zaleplon can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydromorphine.
DiltiazemThe metabolism of Zaleplon can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Doxepin.
DoxycyclineThe metabolism of Zaleplon can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
DoxylamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Zaleplon is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
DronedaroneThe metabolism of Zaleplon can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Zaleplon.
DrotebanolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zaleplon.
EcgonineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Zaleplon is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Zaleplon can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Zaleplon is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Zaleplon.
EntacaponeThe risk or severity of adverse effects can be increased when Zaleplon is combined with Entacapone.
EnzalutamideThe serum concentration of Zaleplon can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Zaleplon can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Zaleplon is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Zaleplon can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zaleplon.
EthanolZaleplon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Zaleplon.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zaleplon.
EthosuximideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Zaleplon.
EtoperidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etorphine.
EtravirineThe serum concentration of Zaleplon can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zaleplon.
FexofenadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flibanserin.
FluconazoleThe metabolism of Zaleplon can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fludiazepam.
FlumazenilFlumazenil may decrease the sedative activities of Zaleplon.
FlunarizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zaleplon.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zaleplon.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zaleplon.
FluspirileneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluvoxamine.
FluvoxamineThe metabolism of Zaleplon can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Zaleplon can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Zaleplon can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fospropofol.
Fusidic AcidThe serum concentration of Zaleplon can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Zaleplon is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Zaleplon is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Zaleplon.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zaleplon.
HalothaneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Zaleplon.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zaleplon.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
HydroxyzineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Hydroxyzine.
IdelalisibThe serum concentration of Zaleplon can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Iloperidone.
ImatinibThe metabolism of Zaleplon can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Indalpine.
IndinavirThe metabolism of Zaleplon can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Zaleplon can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Zaleplon.
IsradipineThe metabolism of Zaleplon can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Zaleplon can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Zaleplon can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketobemidone.
KetoconazoleThe metabolism of Zaleplon can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zaleplon.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zaleplon.
LithiumThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lofentanil.
LopinavirThe metabolism of Zaleplon can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zaleplon.
LovastatinThe metabolism of Zaleplon can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zaleplon.
Lu AA21004The risk or severity of adverse effects can be increased when Zaleplon is combined with Lu AA21004.
LuliconazoleThe serum concentration of Zaleplon can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Medetomidine.
MefloquineThe therapeutic efficacy of Zaleplon can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Zaleplon is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zaleplon.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zaleplon.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zaleplon.
MetaxaloneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Zaleplon.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Zaleplon.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zaleplon.
MetyrosineZaleplon may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Zaleplon can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zaleplon.
MifepristoneThe metabolism of Zaleplon can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Zaleplon is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
MirtazapineZaleplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zaleplon.
MitotaneThe serum concentration of Zaleplon can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Zaleplon can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Zaleplon.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
NabiloneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nabilone.
NafcillinThe serum concentration of Zaleplon can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zaleplon.
NefazodoneThe metabolism of Zaleplon can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Zaleplon can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Zaleplon can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Zaleplon can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Zaleplon can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Olanzapine.
OlaparibThe metabolism of Zaleplon can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zaleplon.
OpiumThe risk or severity of adverse effects can be increased when Zaleplon is combined with Opium.
OrlistatThe serum concentration of Zaleplon can be decreased when it is combined with Orlistat.
OrphenadrineZaleplon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zaleplon.
OsanetantThe risk or severity of adverse effects can be increased when Zaleplon is combined with Osanetant.
OsimertinibThe serum concentration of Zaleplon can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zaleplon.
OxprenololThe risk or severity of adverse effects can be increased when Zaleplon is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zaleplon.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zaleplon.
OxymorphoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Oxymorphone.
PalbociclibThe serum concentration of Zaleplon can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paliperidone.
ParaldehydeZaleplon may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Zaleplon.
ParoxetineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zaleplon.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zaleplon.
PerampanelThe risk or severity of adverse effects can be increased when Zaleplon is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Zaleplon is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zaleplon.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zaleplon.
PhenobarbitalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pomalidomide.
PosaconazoleThe metabolism of Zaleplon can be decreased when combined with Posaconazole.
PramipexoleZaleplon may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zaleplon.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Zaleplon.
PrimidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Zaleplon.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zaleplon.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Zaleplon.
PromethazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zaleplon.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Zaleplon.
PropoxycaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Zaleplon is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ramelteon.
RanolazineThe metabolism of Zaleplon can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zaleplon.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zaleplon.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zaleplon.
RifabutinThe serum concentration of Zaleplon can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Zaleplon can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Zaleplon can be decreased when it is combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Zaleplon.
RitonavirThe metabolism of Zaleplon can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Romifidine.
RopiniroleZaleplon may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zaleplon.
RotigotineZaleplon may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zaleplon.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Zaleplon is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Zaleplon can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zaleplon.
SertindoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sevoflurane.
SildenafilThe metabolism of Zaleplon can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Zaleplon can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Zaleplon can be increased when it is combined with Simeprevir.
Sodium oxybateZaleplon may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Zaleplon.
St. John's WortThe serum concentration of Zaleplon can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon.
SulfisoxazoleThe metabolism of Zaleplon can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zaleplon.
SuvorexantThe risk or severity of adverse effects can be increased when Zaleplon is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tasimelteon.
TelaprevirThe metabolism of Zaleplon can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Zaleplon can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zaleplon.
TetrabenazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrodotoxin.
ThalidomideZaleplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zaleplon.
ThiamylalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Zaleplon.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zaleplon.
ThiothixeneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tiagabine.
TiclopidineThe metabolism of Zaleplon can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tizanidine.
TocilizumabThe serum concentration of Zaleplon can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zaleplon.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zaleplon.
TrazodoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zaleplon.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zaleplon.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zaleplon.
TrimipramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Zaleplon.
VenlafaxineThe metabolism of Zaleplon can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Zaleplon can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Vilazodone.
VoriconazoleThe metabolism of Zaleplon can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Xylazine.
ZiconotideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zimelidine.
ZiprasidoneThe metabolism of Zaleplon can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zaleplon.
ZonisamideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Patat A, Paty I, Hindmarch I: Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol. 2001 Jul;16(5):369-392. [PubMed:12404558 ]
  4. Barbera J, Shapiro C: Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf. 2005;28(4):301-18. [PubMed:15783240 ]
  5. Sanger DJ, Griebel G, Perrault G, Claustre Y, Schoemaker H: Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity. Pharmacol Biochem Behav. 1999 Oct;64(2):269-73. [PubMed:10515302 ]
  6. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L: New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26(4):261-82. [PubMed:12608888 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
other
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Foye, William O.;Williams, David A.;Lemke, Thomas L. (2002). Foye's Principles of Medicinal Chemistry (5th ed.). Lippincott Williams & Wilkins. [ISBN:0683307371 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xanthine dehydrogenase activity
Specific Function:
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyz...
Gene Name:
AOX1
Uniprot ID:
Q06278
Molecular Weight:
147916.735 Da
References
  1. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, Scatina JA: Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 2002 Oct;32(10):835-47. [PubMed:12419014 ]
  2. Obach RS: Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos. 2004 Jan;32(1):89-97. [PubMed:14709625 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23